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1.  Introduction  
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter referred to as the 
‘Decision’) stipulates that ‘Where Europol and the EMCDDA, or the Council, acting by 
a majority of its members, consider that the information provided by the Member 
State on a new psychoactive substance merits the collection of further information, 
this information shall be collated and presented by Europol and the EMCDDA in the 
form of a Joint Report (hereinafter the ‘Joint Report’).’ The Joint Report shall be 
submitted to the Council, the European Medicines Agency (EMA) and the European 
Commission. 
At the end of September 2013, the EMCDDA and Europol examined the available 
information on a new psychoactive substance 3,4-dichloro-N-[[1-
(dimethylamino)cyclohexyl]methyl]benzamide, commonly abbreviated as AH-7921, 
through a joint assessment based upon the following criteria: 
1. the amount of the material seized; 
2. evidence of organised crime involvement; 
3. evidence of international trafficking; 
4. analogy with better-studied compounds; 
5. evidence of the potential for further (rapid) spread; and, 
6. evidence of cases of serious intoxication or fatalities. 
The EMCDDA and Europol agreed that the information collected on AH-7921 
satisfied criteria 4, 5 and 6. The two organisations therefore concluded that sufficient 
information had been accumulated to merit the production of a Joint Report on AH-
7921 as stipulated by Article 5.1 of the Decision. 
2. Information collection process 
In compliance with the provisions of the Decision, on 7 October 2013 the EMCDDA 
and Europol launched a procedure for the collection of information on AH-7921, in 
order to prepare the Joint Report. The information was collected mainly through the 
Reitox National Focal Points in the Member States, Turkey and Norway as well as 
the Europol National Units. In addition, the EMA collected information through the 
national competent authorities responsible for human and veterinary medicinal 
products in the Member States as well as in Norway and Iceland. The information 
collection process was largely concluded by 18 November 2013; additional 
 
(1) OJ L 127, 20.5.2005, p. 32.  
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information and clarifications from some countries were received up to four weeks 
after this date. 
Europol asked the Europol National Units to provide information on: 
• the level of production of AH-7921 in their country; 
• the level of distribution of AH-7921 in their country; 
• the level of trafficking of AH-7921 in their country, both for internal, transit or 
export purposes; 
• the number of seizures of AH-7921 in their country, the total amount of the 
seizures, country of origin, details on the physical forms (including photos); 
• the role of organised crime, or criminal groups, in the production, distribution 
and trafficking of AH-7921 in their country; and, 
• any known aspect of violence and/or money laundering relating to the 
production and trafficking of AH-7921. 
Europol received responses from 15 Member States. 
According to Article 5.3 of the Decision, the EMA requested that the national 
competent authorities responsible for human and veterinary medicinal products in the 
Member States and in Norway and Iceland provide information on whether: 
• the new psychoactive substance AH-7921 has obtained a marketing 
authorisation; 
• the new psychoactive substance AH-7921 is the subject of an application for 
a marketing authorisation; and, 
• a marketing authorisation that had been granted in respect of the new 
psychoactive substance AH-7921 has been suspended. 
Twenty-four Member States (2), Norway and Iceland replied to the EMA’s request 
regarding human and/or veterinary medicinal products. The EMA also provided 
information as relevant to the central authorisation procedure. 
Furthermore, in anticipation of Article 7.3 of the Decision in relation to the 
manufacturing of medicinal products in the European Union, the EMA also requested 
information on whether the new psychoactive substance AH-7921 is used to 
manufacture a medicinal product: 
• which has been granted a marketing authorisation; 
 
(2)  Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, 
Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Poland, Portugal, 
Slovakia, Slovenia, Spain, Sweden, and the United Kingdom. 
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• for which an application has been made for a marketing authorisation; and, 
• for which a marketing authorisation has been suspended by a competent 
authority. 
Twenty-three Member States (3), Norway and Iceland replied to the EMA’s request in 
this regard. The EMA also provided information as relevant to the central 
authorisation procedure. 
The EMCDDA collected data through: 
1. a structured questionnaire from the Reitox National Focal Points. The EMCDDA 
received replies from 28 Member States as well as Norway and Turkey; 
2. data previously provided to the EU Early Warning System in EMCDDA-Europol 
Reporting Forms, EWS Progress and Final Reports;  
3. a specific information request to the World Health Organization on whether or not 
AH-7921 is under assessment by the United Nations system (see section 3.5), 
and, 
4. a structured search of the scientific literature and of relevant Internet sites. 
In addition, some sections of the Joint Report (4) have been adapted from a review 
commissioned by the EMCDDA (Ujváry, 2013). 
Thus, information included in sections 3.2.1 and 3.3 of the Joint Report was provided 
by Europol, while the EMCDDA provided information included in sections 3.1, 3.2.2, 
3.4, 3.5, 3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information included in sections 
3.8.3 (in part), 4.1, 4.2 and 4.3 was provided by the EMA. The conclusion of the Joint 
Report was prepared and agreed by the two organisations responsible — the 
EMCDDA and Europol. Further details of the seizures and collected samples 
(including images where available) reported to the EMCDDA are provided in Annex 
1. The details of deaths associated with AH-7921 that have been reported to the 
EMCDDA are provided in Annex 2. 
3.  Information required by Article 5.2 of the Decision 
 
The order and titles of subsections 3.1 to 3.8 and section 4 below are as they appear 
in Article 5.2(a) to (h) and Article 5.3(a) to (c) of the Decision; sections are cross-
referenced with those set down in the Decision. 
 
(3)  Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Germany, Greece, 
Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Poland, Portugal, Slovakia, 
Slovenia, Spain, Sweden, and the United Kingdom. 
(4) Notably information on the pharmacology and mode of action, toxicology, dependence and 
abuse potential, and the subjective effects of AH-7921. 
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3.1 Chemical and physical description, including the names under which 
the new psychoactive substance is known — Article 5.2(a) of the 
Decision 
 
Chemical description and names 
 
AH-7921 is an N-substituted cyclohexylmethylbenzamide, where the benzamide 
moiety is dichlorinated at positions 3 and 4 of the ring and the aminocyclohexane 
moiety is N,N-dimethylated. 
 
In the commonly used name AH-7921, ‘AH’ refers to ‘Allen & Hanburys’, the 
company that patented the drug. Another name used is doxylam; this may be easily 
confused with ‘doxylamine’, which is the International Nonproprietary Name (INN) of 
a chemically different and widely used antihistaminic medicine with sedative-hypnotic 
properties. 
 
The systematic IUPAC name for AH-7921 is 3,4-dichloro-N-{[1-
(dimethylamino)cyclohexyl]methyl}benzamide. 
 
Additional chemical synonyms have been reported: 
 
3,4-dichloro-N-[[1-(dimethylamino)cyklohexyl]methyl]bensamid 
3,4-dikloori-N-[(1-dimetyyliamino)sykloheksyyli-metyyli]bentsamidi (Finnish) 
1-(3,4-dichlorobenzamidomethyl)cyclohexyldimethylamine 
 
Furthermore, common names or codenames have also been reported: doxylam and 
CN 2924 29 98. 
 
Finally, the following street names have been reported: ‘AH-7921’ and ‘doxylan’. 
 
Figure 1. The molecular structure of AH-7921 
 
 
 
Molecular formula: C16H22Cl2N2O 
 
Molecular weight: 329.26 
 
Chemical Abstract Service registry numbers 
 
55154-30-8  free base 
41804-96-0  hydrochloride salt 
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The REACH registered substances database hosted by the European Chemicals 
Agency (ECHA) was searched using the CAS registry numbers listed above. The 
search returned no results. 
 
Physical description  
 
The free base form of AH-7921 is a solid; its melting point is not known. The 
hydrochloride salt, also a solid, has been documented to have a melting point of 215-
216oC. 
 
An Internet search conducted by the EMCDDA found that AH-7921 is being offered 
for sale as the free base and the hydrochloride salt form. 
 
Information provided from seizures and collected samples have usually noted the 
presence of AH-7921 in powder form. In one case it was also detected in a sample 
taken from a syringe that was recovered from the scene of a death. 
 
A detailed description of AH-7921 seizures and collected samples that have been 
encountered can be found in subsections 3.2.1 and 3.2.2 below.  
3.2  Information on the frequency, circumstances and/or quantities in which 
a new psychoactive substance is encountered, and information on the 
means and methods of manufacture of the new psychoactive substance 
— Article 5.2(b) of the Decision 
3.2.1 Information provided to Europol 
Europol received replies from 15 Member States (Belgium, Bulgaria, Croatia, Cyprus, 
Estonia, Finland, Germany, Hungary, Italy, Latvia, Lithuania, Luxembourg, Poland, 
Slovakia and Slovenia). Of these, Finland and Germany provided information relating 
to AH-7921. 
The level of production, distribution and trafficking 
Finland reported three seizures of AH-7921 totalling 3.1 grams of powder. 
 
Germany reported four seizures of AH-7921 which ranged from 2.8 grams to 9.81 
grams. All seizures were made in 2013. 
No reports were received that indicated licit or illicit production of AH-7921 in Finland 
or Germany.  
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3.2.2  Information provided to the EMCDDA 
Seven Member States (Austria, Denmark, Finland, France, Germany, Sweden, and 
the United Kingdom) and Norway reported detections of AH-7921 (5). 
Seizures  
Six Member States and Norway reported seizures of AH-7921: Austria (2 seizures); 
Denmark (1); Finland (6); France (1); Germany (4); Sweden (10); and, Norway (4).  
AH-7921 has usually been seized in powder form. In one case it was also detected in 
a sample taken from a syringe found at the scene of a death. 
Where information has been provided, quantities of powder ranged from 0.02 grams 
(Sweden) to 500 grams (France). Caffeine was the only additional substance to have 
been reported in two seizures reported by Sweden. 
Austria reported two seizures of powder of 0.9 grams and 1.9 grams, seized by the 
police in August and September 2013. 
Denmark reported a seizure of 0.87 grams of powder, seized by the police in 21 May 
2013. 
Finland reported five seizures made by customs authorities at Helsinki airport 
(freight) and one seizure from the police, between October 2012 and October 2013. 
Quantities seized were small, ranging from 0.1 grams to 2 grams. 
France reported one seizure of 500 grams of powder, seized by customs authorities 
in freight at Roissy Airport (Paris) in October 2013. 
Germany reported four seizures of powder, weighing from 2.8 grams to 9.81 grams, 
seized in February and October 2013. 
Sweden reported a total of 10 seizures made during 2012 and 2013. Five were made 
by the police (from 0.02 to 12.94 grams) and five by customs authorities (from 0.2 to 
103.86 grams). Caffeine was also detected in two of the samples seized by customs. 
Norway reported four seizures made by police. The quantities seized ranged from 
0.23 grams to 1 gram. The first seizure was made in December 2012. In this case, a 
ziplock bag containing a white powder along with a used syringe that both contained 
AH-7921 were recovered from the scene of a death (see details in section 3.4.1).  
 
(5) ‘Detections’ is an all-encompassing term and may include seizures and/or collected and/or 
biological samples. Seizure means a substance available (seized) through law enforcement 
activities (police, customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, blood, etc.) and/or 
specimens (tissues, hair, etc.)  
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Biological samples 
Two Member States (Sweden and the United Kingdom) and Norway reported 
detections of AH-7921 in biological samples. 
Sweden reported five non-fatal intoxications that occurred between December 2012 
and 30 March 2013 where AH-7921 was detected. 
Sweden, the United Kingdom and Norway reported a total of 15 deaths where AH-
7921 was detected (Sweden, 10 deaths (6); the United Kingdom, 3; Norway, 2) (see 
section 3.4.1 and Annex 2 for further details).  
Sweden reported two detections of AH-7921 in the urine of two persons suspected of 
committing minor criminal offences. 
Collected samples  
The United Kingdom reported a collected sample of AH-7921 purchased from an 
Internet retailer in July 2012 (7). This sample formed the basis of the first notification 
of detection of AH-7921 in the European Union (see section 2.6 for further details). 
The product was supplied in a ziplock bag as a white powder and cost 10 GBP 
(approximately 11.93 EUR) for 250 milligrams. Further details of this sample are 
provided in Annex 1. 
3.3 Information on the involvement of organised crime in the manufacture 
or trafficking of the new psychoactive substance — Article 5.2(c) of the 
Decision 
Germany reported that no links have been identified between organised crime groups 
and the production, trafficking and/or distribution of AH-7921. They also noted that it 
should be borne in mind that given the easy access to substances (which can be in 
large amounts) via Internet retailers it cannot be excluded that a certain level of 
organisation may exist. In addition, the interest and presence of organised crime 
groups in the phenomenon of new psychoactive substances can be easily concluded 
from the substantial profits that can be obtained from this type of activity. 
Money laundering aspects 
No information was received on money laundering in connection with the production 
and/or trafficking of AH-7921. 
 
(6) Sweden also reported one death that occurred in Norway where the post-mortem biological 
sample was analysed by the Swedish National Laboratory of Forensic Medicine. At this time it 
is not clear if this case relates to one of the deaths reported by Norway (below) or is an 
additional death.  
(7) Purchased from buyresearchchemicals.co.uk 
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Violence in connection with production, wholesale and distribution 
No information was received on incidents of violence in connection with the 
production, wholesale and/or trafficking of AH-7921. 
3.4 A first indication of the risks associated with the new psychoactive 
substance, including the health and social risks, and of the 
characteristics of users — Article 5.2(d) of the Decision   
3.4.1 First indication of health risks 
A total of six non-fatal intoxications and 15 deaths associated with AH-7921 were 
reported by Sweden, the United Kingdom and Norway. Not all of these cases have 
been analytically confirmed. See Annex 2 for further details on the deaths. 
Non-fatal intoxications 
Sweden 
Sweden reported six non-fatal intoxications associated with AH-7921 reported by the 
Swedish Poison Information Centre between December 2012 and 30 March 2013. 
The presence of AH-7921 was analytically confirmed in five of the six cases. No 
information was provided on whether the AH-7921 was quantified in these five cases. 
No further details are currently available on these cases. 
Deaths 
Sweden 
Sweden reported 10 deaths associated with AH-7921 that occurred between January 
2013 and September 2013 (8). All of these cases were analytically confirmed. In nine 
of the cases, the concentration of AH-7921 in post-mortem femoral blood ranged 
from 0.03 to 0.99 µg/g; in the remaining case AH-7921 was detected in post-mortem 
hair but was not quantified. In all 10 cases AH-7921 was found in combination with at 
least one other psychoactive substance. These included: amphetamine (2 cases); 3-
methylmethcathinone (2); a metabolite of ketamine; alcohol; buprenorphine; 
benzodiazepines (alprazolam, diazepam, nordazepam, pyrazolam) and other 
medicines (zopiclone, paroxetine, bupropion, mirtazapine, pregabalin, gabapentin, 
aripiprzol). The cause of death was provided for six cases: ‘toxic effect of AH-7921’; 
‘overdose of AH-7921’; ‘unintentional overdose’, ‘overdose of benzodiazepines and 
opiates’, ‘intoxication with opioids among others’ and ‘pneumonia caused by 
 
(8)  As noted in section 3.2.2 ‘biological detections’, Sweden also reported one death that occurred 
in Norway where the post-mortem biological sample were analysed by the Swedish National 
Laboratory of Forensic Medicine. AH-7921 was detected in femoral blood and quantified at 
0,34 µg/g femoral blood; etizolam was also detected and quantified at 0,27 µg. At this time it is 
not clear if this case relates to one of the deaths reported by Norway (below) or is an additional 
death. 
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aspiration’. In one case the cause of death was reported as ‘unclear’. In two cases 
the cause of death remains to be determined. In one death no further information 
was provided. 
United Kingdom 
The United Kingdom reported three deaths associated with AH-7921. The dates of 
death were not reported, but they are thought to have occurred between January and 
November 2013. All of these cases were analytically confirmed. 
In the first case AH-7921 was detected in blood with a concentration of 0.58 mg/L. 
The deceased was found dead at home. 4-MEC (9), pentedrone, mephedrone, D2PM 
(10), etizolam and etaqualone were also detected in post-mortem blood. 
In the second case AH-7921 was detected in blood with a concentration of 0.05 
mg/L. The deceased was found dead with bag over the head and chloroform was 
also involved.  
In the third case AH-7921 was detected in blood with a concentration of 4.46 mg/L. 
The victim was found unresponsive at home and died in hospital. Clobazam, 
doxylamine and mirtazapine were also detected in post-mortem blood.  
Norway 
Norway reported two deaths associated with AH-7921. The first death occurred in 
December 2012; the second in August 2013.  
In the first case AH-7921 was not analytically confirmed but was suspected due to 
the circumstances of the death. During the investigation the police found a bag with 
small amounts of white powder, and a used syringe with dried blood close to the 
deceased. AH-7921 was detected in both the powder and a sample taken from the 
syringe. Etizolam and phenazepam were also found at the scene. 
In the second case the presence of AH-7921 was analytically confirmed. The level of 
AH-7921 was quantified at 1.3 µmol/L. Other substances were also present 2-
fluoromethamphetamine (0.041 µmol/L), 3-methylmethcathinone (0.012 µmol/L), 
codeine (1.4 µmol/L) and paracetamol (124 µmol/L). There was information that the 
deceased had bought drugs on the Internet.  
See Annex 2 for further details of these cases. 
Pharmacology and mode of action 
 
(9)  4-Methylethcathinone. 
(10)  Diphenylprolinol. 
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In the early 1970s a series of benzamide derivatives with an aminocyclohexane 
moiety were invented, inspired by the analgesic and other therapeutically valuable 
properties of substances structurally related to fentanyl and phencyclidine (Harper 
and Veitch, 1976; Harper et al., 1974). The most active compound in the series was 
AH-7921 (Figure 1). Laboratory experiments with animals established AH-7921 to be 
an opioid receptor agonist with analgesic potency similar to that of morphine. 
However, the development of the substance was abandoned and only limited 
information on its biological properties is available. Since 1988, no studies with AH-
7921 or its analogues appear to have been published in the scientific literature. 
Of the 57 cyclohexyl derivatives tested, AH-7921 showed significant analgesic 
properties being nearly as active as morphine in several pain models. The analgesic 
potencies found for morphine and AH-7921 in the initial studies with mice and rats 
are given in Table 1 (Tyers, 1980; Harper et al., 1974; Brittain et al., 1973). 
Table 1. Analgesic potencies (ED50 values in mg/kg) of morphine and AH-7921 in 
rodents (representative data). Abbreviations: s.c.: subcutaneous. 
Compound 
Hot-plate test 
mouse, s.c. 
Tail-flick test 
55oC, rat, s.c. 
Phenylquinone 
test, mouse, oral 
Acetylcholine-induced 
writhing, mouse s.c. 
Inflamed paw 
pressure, rat, s.c. 
morphine 1.7 0.6 1.1 0.45 0.43 
AH-7921 1.8 0.8 0.85 0.59 0.57 
In rhesus monkeys, the minimal antinociceptive doses of morphine and AH-7921 to 
suppress pain evoked by electric stimulation of the dental pulp were <5.0 and 
13.8±1.2 mg/kg, respectively (Brittain et al., 1973). 
Comparative pharmacological evaluation with rodents indicated that AH-7921, like 
morphine, is a µ opioid peptide (MOP) receptor agonist. Its analgesic effect against 
chemically-induced pain indicates the involvement of κ opioid peptide (KOP) 
receptors as well (Tyers, 1980) that was confirmed in subsequent studies in vitro with 
guinea pig brain preparations in which AH-7921 showed moderate selectivity towards 
MOP receptors over KOP receptors (Ki = 10 nM versus 150 nM) (Loew et al., 1988). 
Hayes and Tyers (1983) studied in the mouse the role of opioid receptor types in the 
various side effects produced by selected opioid receptor agonists, including AH-
7921, applied subcutaneously. In general, the side effects (e.g., changes in pupil 
diameter and respiratory rate) for AH-7921 and morphine were similar indicating a 
shared mode of action at the receptor level. All the effects produced by the drugs 
were reduced significantly by simultaneous administration of the opioid receptor 
antagonist naloxone (1 mg/kg s.c.). It is noteworthy, that the dose-response curves 
for AH-7921 were rather steep: doses that produced side effects were close to those 
producing analgesia (see also Sewell and Spencer, 1974). For example, the ED50 
value for respiratory depression, that is the dose of the drug capable of depressing 
the respiratory rate of the control group by 25%, was 2.5 mg/kg, for analgesia the 
ED50 value was 0.55 mg/kg; in the case of morphine the ED50 values for respiratory 
13 
depression and analgesia were 4.2 and 0.45 mg/kg, respectively. No studies were 
identified that have examined the pharmacology and mode of action of AH-7921 in 
humans. 
Toxicology 
The study by Harper et al., (1974) implies that the LD50 of AH-7921 is higher than 10 
mg/kg upon intravenous administration in the rat (11). No studies were identified that 
have examined the toxicity of AH-7921 in humans.  
Insufficient information is available to determine the clinical features of acute toxicity 
associated with AH-7921. 
Dependence and abuse potential 
Brittain et al., (1973) assessed the dependence liability of AH-7921 in the rat and 
rhesus monkey. Naloxone-treatment of rats that had received repeated doses of AH-
7921 (5–20 mg/kg orally, three times a day for five days) showed ‘abstinence 
syndrome’ similar to that observable for morphine using a similar dose schedule. 
Nalorphine, another opioid receptor antagonist, evoked withdrawal symptoms in 
rhesus monkeys that had received repeated doses of AH-7921 (7.5–30 mg/kg s.c., 
twice daily for 30 days). Furthermore, single doses of AH-7921 (5–10 mg/kg s.c.) 
completely alleviated the abstinence syndrome in morphine-dependent rhesus 
monkeys. The study concluded that AH-7921 “would be classified as a narcotic 
analgesic having high addictive liability”. No studies were identified that have 
examined the dependence and abuse potential of AH-7921 in humans. 
Some self-reported user experiences suggest development of tolerance, taking more 
than was planned and withdrawal-like symptoms (Google, 2013a,b,c). 
3.4.2 Characteristics of users 
No studies were identified that examined the characteristics of users of AH-7921. 
The section below includes a discussion of the characteristics of users which include 
self-reported use from Internet drug discussion forums and related websites 
(hereafter ‘user websites’). As such it is important to note that it is not possible to 
confirm the specific substance(s) used, nor the purity, dose, etc. Analysis of products 
containing new psychoactive substances that are sold on the drug market have 
shown that the composition can differ between that claimed by the retailer, as well as 
differ over different geographical areas and time. In addition, the information provided 
on user websites should be regarded as illustrative only and not taken as 
representative of users of AH-7921 in general. 
Route of administration, dose and drug regimens 
 
(11) For comparison, LD50 values of morphine (rat, i.v.) ranges between 64 to 223 mg/kg depending 
upon which salt of the drug and which strain of rat are used (Strandberg et al., 2006; 
Niemegeers et al., 1976. Finnegan et al., 1948). 
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Information provided by the Member States, as well as from user websites suggests 
the route of administration for AH-7921 include nasal, oral or sublingual intake, as 
well as intravenous injection and rectal administration. Information from user 
websites suggest a range of doses are used; see ‘subjective effects’, below, for 
examples (Erowid, 2013a; Google, 2013a,b,c). 
Information from user websites suggest that AH-7921 may be used on its own as well 
as in combination with other psychoactive substances, including new psychoactive 
substances and/or controlled drugs (Erowid, 2013; Google, 2013a; Google, 2013b; 
Google, 2013c). In some of the deaths reported by the Member States and Norway 
new psychoactive substances and/or controlled drugs were detected in biological 
samples (Section 3.4.1 and Annex 2). 
Subjective effects 
No studies were identified that have examined the subjective effects of AH-7921 in 
humans; information is limited to self-reported experiences (‘trip reports’) on user 
websites (Erowid, 2013a; Google, 2013a; Google, 2013b; Google, 2013c).  
In January 2012, an ex-heroin user reported the intravenous injection of 100–150 mg 
of a solution of AH-7921 that produced “a lovely smack-like high… complete with 
nod, decent euphoria and the hallmarks of a quality Morphine/bordering Diamorphine 
high”; development of tolerance was noted after repeated use of AH-7921 alone and 
in combination with ethylphenidate (‘speedballing’) (Drugs-Forum, 2013). A separate 
report described the inhalation of the vapours of a total of 40 mg of the free amine 
(free base) of AH-7921 (powdery crystal). The peak-effects lasted for 1.5 h and were 
described as “like a relaxed morphine effect” (Erowid, 2013b). Another report 
described the experiences of two users who sublingually applied a solution made 
from 1 g of the powdery crystal (the CAS registration number provided by the vendor 
indicated the HCl salt form), lemon juice (10 ml) and warm water (40 ml). After the 
initial sublingual doses of 2 ml of the solution (containing 40 mg of the drug), total 
amounts of about 145 and 155 mg of the drug were consumed during an 11 h 
session by the users (redosing was done in 60 to 120 minutes intervals). In addition 
to analgesia, relaxation, euphoria, “opiate glow” and alertness, occasional itching, 
nausea and, toward the end of the session, tremors were experienced. Slight miosis 
was noted three hours after the first dose (Erowid, 2013c). No serious adverse 
events were mentioned in these three reports. 
Availability and supply 
A search of google.com using the search string "buy "AH-7921"" conducted in 
December 2013 for the Joint Report identified a number of Internet retailers offering 
AH-7921 for sale in both retail and wholesale quantities (Google, 2013d). In the 
former case AH-7921 appears to be usually sold as a ‘research chemical’. As noted, 
the first detection of AH-7921 reported to the EMCDDA was a collected sample of 
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250 milligrams of white powder purchased in July 2012 for 10GBP (11.98EUR) from 
an Internet retailer selling ‘research chemicals’ (12). 
Prevalence of use 
Data from prevalence surveys 
No prevalence surveys were identified that have examined the use of AH-7921 in the 
general population or in targeted populations. 
3.5 Information on whether or not the new substance is currently under 
assessment, or has been under assessment, by the UN system — 
Article 5.2(e) of the Decision 
The World Health Organization is the specialised United Nations agency designated 
for the evaluation of the medical, scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 1961 and the 
Convention on Psychotropic Substances, 1971. On 10 October 2013, the World 
Health Organization informed the EMCDDA that AH-7921 is currently under 
assessment and ’the critical review report will be published only early next year 
(probably April)’.  
Article 7.1 of Council Decision states that ‘no risk assessment shall be carried out in 
the absence of a Europol/EMCDDA Joint Report. Nor shall a risk assessment be 
carried out where the new psychoactive substance concerned is at an advanced 
stage of assessment within the United Nations system, namely once the WHO expert 
committee on drug dependence has published its critical review together with a 
written recommendation, except where there is significant new information that is 
relevant in the framework of this Decision’.  
The Joint Report has been produced on the understanding that AH-7921 is not at an 
advanced stage of assessment within the United Nations system. 
3.6 The date of notification on the Reporting Form of the new psychoactive 
substance to the EMCDDA or to Europol — Article 5.2(f) of the Decision 
The first official EMCDDA–Europol notification of AH-7921 dates from August 2012 
from the United Kingdom National Focal Point. The Reporting Form details a 
collected sample of 250 milligrams of white powder purchased in July 2012 from an 
Internet retailer (13) at a cost of 10GBP (11.98EUR). It was sold as AH-7921 and was 
received in packaging with a label indicating that it was for use as a ‘Laboratory 
reagent only’. Other details included the full chemical name and hazard warning 
 
(12)  Purchased from http://www.buyresearchchemicals.co.uk 
(13)  Purchased from http://www.buyresearchchemicals.co.uk 
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codes. The identification and analytical characterization was based on GC-MS (14), 
1H NMR (15) and DEPTQ NMR (16). 
AH-7921 was added to the list of new psychoactive substances monitored by the 
EMCDDA and Europol through the European Union Early Warning System and a 
profile of the substance was created in the EMCDDA European Database on New 
Drugs (EDND). Since then analytical details, background information and public 
health alerts have been exchanged between EMCDDA, Europol and the Member 
States on an ad hoc basis. The European Commission and the EMA were kept duly 
informed. 
3.7 Information on whether or not the new psychoactive substance is 
already subject to control measures at national level in a Member State 
— Article 5.2(g) of the Decision 
Sweden reported that AH-7921 is a controlled under the Narcotic drugs control Act 
(SFS 1992-860) and the Narcotic drugs control Ordinance (SFS 1994:1554). 
Two Member States (Poland and Romania) reported that AH-7921 is controlled 
under legislation prohibiting the unauthorised supply of defined or qualifying new 
psychoactive substances. In Poland, AH-7921 falls under the definition of a 
‘substitution drug’ under the Act amending the Act on counteracting drug addiction 
and the Act on State Sanitary Inspection, 2010 and as such its marketing and 
production is penalized with a fine (administrative sanctions). In Romania the Law 
194/2011 subjects to control any psychoactive substance that qualifies by conforming 
to certain criteria (all substances with psychoactive potential are subject to control 
until proven harmless by a special designated commission). 
Two Member States (Finland and the Netherlands), and Norway reported that AH-
7921 is subject to control measures under medicine legislation. In Finland AH-7921 
has been controlled under the Medicines Act (395/87) since 15 March 2013. In the 
Netherlands, the sale of AH-7921 in consumer amounts it is treated as being a 
medicinal product and must comply with medicines legislation (and general product 
safety legislation). In Norway, AH-7921 is regulated by the Medicines Act and a 
prescription would be required to receive it. 
Twenty-two Member States (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, France, Germany (17), Greece, Hungary, Ireland, Italy, 
Latvia, Lithuania, Luxembourg, Malta, Portugal, Slovakia, Slovenia and the United 
Kingdom) and Turkey reported that AH-7921 is not subject to control measures at the 
national level. 
 
(14)  Gas chromatography-mass spectrometry 
(15)  Proton nuclear magnetic resonance spectroscopy 
(16) Distortionless enhancement by polarizaton transfer with quaternary carbons NMR 
(17)  Germany reported that there is an intention to introduce national control measures for AH-
7921. 
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No information was provided regarding the control status of AH-7921 in Spain. 
3.8 Further information — Article 5.2(h) of the Decision 
3.8.1 The chemical precursors that are known to have been used for the 
manufacture of the substance 
 
No information was reported about the chemical precursors or manufacturing 
methods used to make AH-7921. Methods for the production of AH-7921 are 
documented in the scientific literature. 
3.8.2 The mode and scope of the established or expected use of the new 
substance 
No studies were identified that have examined the mode and scope of established or 
expected use of AH-7921. Given the limited information currently available, the 
relevant information on the mode and scope of established or expected use of AH-
7921 which has been reported by the Member States as well as that from user 
websites has been included in the previous sections. 
3.8.3 Other use of the new psychoactive substance and the extent of such 
use, the risks associated with this use of the new psychoactive substance, 
including the health and social risks 
 
No information was provided by any Member State that indicated that AH-7921 had 
any other use apart from in legitimate scientific research and as an analytical 
reference standard. 
 
From the available information it does not appear that AH-7921 is used in the 
manufacture of a medicinal product in the European Union. However, the collection 
of information cannot be considered exhaustive in the absence of a European Union 
database on the synthetic routes of all medicinal products (18). 
4. Information from the EMA as requested by Article 5.3 of the Decision 
4.1 Marketing authorisation 
Twenty-four Member States, Norway and Iceland responded to the EMA’s 
information request (see section 2). They reported that the new psychoactive 
substance AH-7921 has not obtained a marketing authorisation (19). The EMA also 
 
(18) i.e. products that have been granted a marketing authorisation, or where an application for a 
marketing authorisation has been made, or where the marketing authorisation has been 
suspended. 
(19) Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, 
Iceland, Ireland, Netherlands, Norway, Portugal, Slovenia, Spain, Sweden and the United 
Kingdom provided responses in relation to both human and veterinary medicinal products. 
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reported that the new psychoactive substance AH-7921 has not obtained a marketing 
authorisation through the central authorisation procedure. 
4.2 Application for a marketing authorisation 
Twenty-four Member States, Norway and Iceland responded to the EMA’s 
information request (see section 2). They reported that the new psychoactive 
substance AH-7921 is not the subject of an application for a marketing authorisation 
(19). The EMA also reported that the new psychoactive substance AH-7921 is not the 
subject of an application for a marketing authorisation through the central 
authorisation procedure. 
4.3 Suspended marketing authorisation 
Twenty-four Member States, Norway and Iceland responded to the EMA’s 
information request (see section 2). They reported that there had been no cases of a 
suspended marketing authorisation that had been granted in respect of the new 
psychoactive substance AH-7921 (19). The EMA also reported that the new 
psychoactive substance AH-7921 is not the subject of a suspended marketing 
authorisation through the central authorisation procedure. 
5. Conclusion 
AH-7921 is a synthetic opioid. It has been available in the European Union since at 
least July 2012 and has been detected in seven EU Member States and Norway. In 
most cases it has been seized in small quantities as a powder. Over a short period of 
time it has been associated with six non-fatal intoxications and fifteen deaths in three 
countries. The similarity of AH-7921 to morphine in terms of pharmacology is a key 
concern. This may play an important role in the further spread of AH-7921 by opioid 
users, including the injecting population. We conclude that the health and social risks 
caused by the manufacture, trafficking and use of AH-7921, as well as the 
involvement of organised crime and possible consequences of control measures, 
could be thoroughly assessed through a risk assessment procedure in accordance 
with Article 6 of Council Decision 2005/387/JHA. 
                                                                                                                                       
Cyprus, Italy, Lithuania, Malta and Slovakia provided responses in relation to human medicinal 
products. France, Latvia and Poland provided responses in relation to veterinary medicinal 
products. In addition the EMA provided information in relation to both human and veterinary 
medicinal products in respect to the central authorisation procedure. 
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Annex 1 
 
 
EMCDDA–Europol Joint Report 
on a new psychoactive substance: AH-7921 
 
 
Images of AH-7921 from seizures and collected samples 
 
 
Country Image Description 
 
Norway 
 
 
 
 
Seizure, December 2012 
One ziplockbag with trace amounts of white powder, 
and one used syringe with deposits of red/brown 
material (assumed to be dried blood), seized in 
Alstahaug. 
Seizing authority: Police 
 
United 
Kingdom 
 
 
 
 
 
Collected sample, analysed in July 2012 
250mg white powder, test purchase (250 mg, £10.00) 
from Buy Research Chemicals 
Collecting authority: States Analyst's Laboratory, 
Guernsey and Liverpool John Moores University 
 
 
 Annex 2. Deaths associated with AH-7921 (1)  
 Country  Date of death 
(gender, age)  
Biological 
sample (2) 
AH-7921 
result (3) 
Results for other substances (4) Notes  
1 Sweden  08-01-2013 (M, 28) 
Femoral 
blood 0.81 µg/g 10 µg gabapentin 
Cause of death reported as ‘unintentional 
overdose’ 
2 Sweden 04-02-2013  (M, 25) 
Femoral 
blood 0.99 µg/g 4.7 µg amphetamine, aripiprzol 
Cause of death reported as ‘pneumonia caused 
by aspiration’ 
3 Sweden  22-02-2013 Femoral blood 0.03 µg/g 0.03 µg paroxetine Cause of death reported as ‘not decided yet’ 
4 Sweden  08-04-2013 Femoral blood 0.2 µg/g pyrazolam, diazepam 
Cause of death reported as ‘overdose of 
benzodiazepines and opiates’ 
5 Sweden 03-05-2013 Femoral blood 0.3 µg/g pyrazolam, alprazolam, zopiclone 
Cause of death reported as ‘overdose of AH-
7921’ 
6 Sweden  15-04-2013 Femoral blood 0.08 µg/g 0.01 µg N-ethylnorketamine, alcohol Cause of death reported as ‘unclear’ 
7 Sweden  16-06-2013 Femoral blood 0.16 µg/g 0.04 µg amphetamine Cause of death reported as ‘not decided yet’ 
8 Sweden  19-06-2013 Femoral blood 0.35 µg/g 3-methylmethcatinone 
Cause of death reported as ‘overdose of AH-
7921’ 
9 Sweden  09-07-2013 Femoral blood 0.43 µg/g 
12 µg/g pregabalin, 0.53 µg/g 
norbupropion, 0.40 µg/g bupropion, 0.17 
µg/g nordiazepam, 0.12 µg/g diazepam, 
mirtazapine and desmethylmirtazapin 
Cause of death reported as ‘intoxication with 
opioids among others’ 
10 Sweden 05/09/2013 Hair + 3-methylmethcatinone, buprenorphine Deceased was treated in intensive care 
23 
 Country  Date of death 
(gender, age)  
Biological 
sample (2) 
AH-7921 
result (3) 
Results for other substances (4) Notes  
11 United Kingdom Jan-Nov 2013 
Blood; 
urine 0.05 mg/L  
Deceased was found dead with bag over head 
and chloroform 
12 United Kingdom Jan-Nov 2013 Blood; urine 0.58 mg/L 
4-MEC, pentedrone, mephedrone, D2PM, 
etizolam, etaqualone Deceased was found dead at home with powders 
13 United Kingdom Jan-Nov 2013 Blood; urine 4.46 mg/L clobazam, doxylamine, mirtazapine 
Subject was unresponsive at home; died in 
hospital 
14 Norway 07-08-2013  (M, 23) 
Peripheral 
blood 1.3 µmol/L 
2-FMA (0.041 µmol/L), 3-MMC (0.012 
µmol/L), codeine (1.4 µmol/L) and 
paracetamol (124 µmol/L) 
There was information that the deceased had 
bought drugs on the internet 
15 Norway (5) Dec 2012 - - - 
Not analytically confirmed. White powder and a 
used syringe with dried blood close to the 
deceased. AH-7921 was detected in both the 
powder and the syringe. 
 
 
1 Sweden reported a death that occurred in Norway where the post-mortem biological sample were analysed by the Swedish National 
Laboratory of Forensic Medicine.  AH-7921 was detected in femoral blood and quantified at 0.34 µg/g femoral blood; etizolam was 
also detected and quantified at 0.27 µg. At this time it is not clear if this case relates to one of this deaths reported by Norway or is 
an additional death. As such it has not been listed in the table. 
2 For the first 14 deaths in this table, the analytical confirmation of AH-7921 was in post mortem samples. 
3 A ‘+’ in this column indicates AH-7921 was detected but no quantification was provided. 
4 4-MEC is 4-methylmethcathinone 
D2PM is diphenyl-2-pyrrolidin-2-yl-methanol 
2-FMA is 2-fluoromethamphetamine 
3-MMC is 3-methylmethcathinone 
5 This death was not analytically confirmed. It has been included because a white powder and a used syringe with dried blood close to 
the deceased were recovered from the scene of death and AH-7921 was detected in both the powder and the syringe. 
